{"id":"W3122624214","doi":"10.1016/s0140-6736(20)32554-x","title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Cancer Care Ontario; Kelowna General Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Ontario Institute for Cancer Research; Incyte; Ipsen; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Regeneron Pharmaceuticals; U.S. Department of Defense; Princess Margaret Cancer Foundation; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Internal medicine; Gemcitabine; Population; Ovarian cancer; Placebo; Clinical trial; Clinical endpoint; Oncology; Cancer; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009241155,0.0005056973,0.002249822,0.00009113362,0.0003324152,0.0001360048,0.0002956774,0.0001846946,0.001787912],"category_scores_gemma":[0.0004696466,0.0002908967,0.0004973229,0.0003329731,0.0000898232,0.0001087258,0.00007787286,0.0004180869,0.00003060226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005869481,"about_ca_system_score_gemma":0.001479185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000208008,"about_ca_topic_score_gemma":0.0009814977,"domain_scores_codex":[0.996751,0.00020778,0.0009719162,0.0007209763,0.0005654489,0.0007829448],"domain_scores_gemma":[0.996491,0.001379109,0.0004694714,0.001114827,0.0002595396,0.0002861252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9538039,0.001495577,0.00003578859,0.0002085296,0.001799427,0.0002057615,0.0005933016,0.00005368038,0.0007178134,0.0006686377,0.02678775,0.01362981],"study_design_scores_gemma":[0.8924888,0.002806779,0.0000625891,0.0004193379,0.001844473,0.00003372019,0.0001598635,0.0006936805,0.001627862,0.000116319,0.09942164,0.0003249205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8650099,0.0203635,0.0008421841,0.06091801,0.006133901,0.03515879,0.00227141,0.0004421593,0.008860118],"genre_scores_gemma":[0.9562565,0.002661652,0.001813382,0.002601939,0.01194472,0.01704596,0.0006802095,0.0001621315,0.006833476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0912466,"threshold_uncertainty_score":0.9999543,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0907230657683899,"score_gpt":0.371654976859516,"score_spread":0.2809319110911261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}